Schroder Investment Management Group
CYTK icon

Schroder Investment Management Group’s Cytokinetics CYTK Stock Holding History

Schroder Investment Management Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Buy
140,099
+121,986
+673% +$8.76M 0.01% 636
2026
Q1 		$1.14M Buy
+18,113
New +$1.15M ﹤0.01% 1016
2025
Q4 		– Sell
-186,883
Closed -$10.1M – 1161
2025
Q3 		$10.1M Sell
186,883
-124,008
-40% -$5.11M 0.01% 661
2025
Q2 		$10.3M Sell
310,891
-34,707
-10% -$1.21M 0.01% 632
2025
Q1 		$14.9M Buy
345,598
+196,165
+131% +$9.02M 0.02% 572
2024
Q4 		$7.05M Buy
149,433
+13,708
+10% +$712K 0.01% 712
2024
Q3 		$7.17M Sell
135,725
-117,762
-46% -$6.56M 0.01% 728
2024
Q2 		$13.7M Hold
253,487
– – 0.02% 569
2024
Q1 		$17.8M Buy
253,487
+142,340
+128% +$11M 0.02% 520
2023
Q4 		$9.28M Buy
+111,147
New +$4.02M 0.01% 646

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schroder Investment Management Group's CYTK Position: Q2 2026 in Review

Schroder Investment Management Group increased its Cytokinetics (CYTK) stake by 673% in Q2 2026, buying an estimated $8.76M and bringing the position to 140,099 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #636.

Schroder Investment Management Group first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $17.8M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Schroder Investment Management Group held 140,099 shares of Cytokinetics worth $12.2M as of Q2 2026.
  • Schroder Investment Management Group bought 121,986 Cytokinetics shares in Q2 2026, an estimated $8.76M.
  • Cytokinetics made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #636 holding.
  • Schroder Investment Management Group first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
  • Schroder Investment Management Group's Cytokinetics position peaked at $17.8M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.